Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation
V Cambiano, A Miners, D Dunn… - The Lancet infectious …, 2018 - thelancet.com
Summary Background In the UK, HIV incidence among men who have sex with men (MSM)
has remained high for several years, despite widespread use of antiretroviral therapy and …
has remained high for several years, despite widespread use of antiretroviral therapy and …
A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia
Background. Antiretroviral therapy (ART) used as preexposure prophylaxis (PrEP) by human
immunodeficiency virus (HIV)–seronegative individuals reduces the risk of acquiring HIV …
immunodeficiency virus (HIV)–seronegative individuals reduces the risk of acquiring HIV …
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study
BE Nichols, CAB Boucher, M van der Valk… - The Lancet Infectious …, 2016 - thelancet.com
Summary Background Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine
prevents HIV infections among men who have sex with men (MSM). PrEP can be given on a …
prevents HIV infections among men who have sex with men (MSM). PrEP can be given on a …
Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study
N Punyacharoensin, WJ Edmunds, D De Angelis… - The lancet HIV, 2016 - thelancet.com
Background HIV transmission in men who have sex with men (MSM) in the UK has shown
no sign of decreasing in the past decade. Additional prevention measures are needed. We …
no sign of decreasing in the past decade. Additional prevention measures are needed. We …
Cost effectiveness of 'on demand'HIV pre‐exposure prophylaxis for non‐injection drug‐using men who have sex with men in Canada
E Ouellet, M Durand, JR Guertin… - Canadian Journal of …, 2015 - Wiley Online Library
BACKGROUND: Recent trials report the efficacy of continuous tenofovir‐based pre‐
exposure prophylaxis (PrEP) for prevention of HIV infection. The cost effectiveness of 'on …
exposure prophylaxis (PrEP) for prevention of HIV infection. The cost effectiveness of 'on …
Optimizing HIV pre‐exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study
Introduction: Once-daily tenofovir/emtricitabine-based pre-exposure prophylaxis (PrEP) can
reduce HIV acquisition in men who have sex with men (MSM), by 44% in the iPrEx trial, and …
reduce HIV acquisition in men who have sex with men (MSM), by 44% in the iPrEx trial, and …
Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study
DC Ten Brink, R Martin-Hughes, ME Minnery… - PLoS …, 2022 - journals.plos.org
Introduction More than 70% of new HIV infections in Asia occurred in eight countries in
2020: Cambodia, China, India, Indonesia, Myanmar, Nepal, Thailand, and Vietnam—with a …
2020: Cambodia, China, India, Indonesia, Myanmar, Nepal, Thailand, and Vietnam—with a …
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective …
Background HIV pre-exposure prophylaxis (PrEP) is highly effective in men who have sex
with men (MSM) at the individual level, but data on population-level impact are lacking. We …
with men (MSM) at the individual level, but data on population-level impact are lacking. We …
Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058
DAMC van de Vijver, AK Richter… - …, 2019 - eurosurveillance.org
Background Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy
for men-who-have-sex-with-men (MSM). The high cost of PrEP has until recently been a …
for men-who-have-sex-with-men (MSM). The high cost of PrEP has until recently been a …
[HTML][HTML] Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label …
S McCormack, DT Dunn, M Desai, DI Dolling, M Gafos… - The Lancet, 2016 - thelancet.com
Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However …
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However …